A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers
Status:
Completed
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
This exploratory phase IIa, double blind, randomized, vehicle controlled, multicenter
dose-finding trial will evaluate the safety, tolerability, and efficacy of FOL-005 topical
formulation (at 0.1%, 0.5% and 1.5% strength) administered once daily (in the evening) for 16
weeks in healthy male subjects with androgenetic alopecia.